Lentiviral Vectors for the Treatment of Fanconi Anemia

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$223,172.00
Award Year:
2010
Program:
STTR
Phase:
Phase I
Contract:
1R41HL099150-01
Agency Tracking Number:
R41HL099150
Solicitation Year:
2010
Solicitation Topic Code:
NHLBI
Solicitation Number:
PA09-114
Small Business Information
RIMEDION, INC.
351 W 10TH ST, STE 514, INDIANAPOLIS, IN, 46202-
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
828836614
Principal Investigator:
DAVID CLAPP
(317) 278-9290
dclapp@iupui.edu
Business Contact:
BUTCH MERCER
(317) 637-9000
butchmercer@rimedion.com
Research Institution:
Indiana University

601 E KIRKWOOD AVE
BLOOMINGTON, IN, 47405-1223
() -
Nonprofit college or university
Abstract
DESCRIPTION (provided by applicant): HIV-1 based lentiviral vectors are becoming an increasingly attractive means of integrating transgenes into target cells. Vectors are in or enterning clinical trials for a diverse group of ailments, including genetic disease, AIDS and cancer. Rimedion and its research partner, Indiana University School of Medicine proposes to develop a novel lentiviral vector for the treatment of Fanconi anemia. While the vector construct will be derived from HIV-1 based lentiviral system, the vector will be pseudotyped with a proprietary viral envelope derived from the human foamy virus. Specific Aim 1: Generate recombinant lentiviral constructs that encode the expression of the FANCA cDNA by the human phosphoglycerate kinase promoter orthe elongation factor 1a promoter and test functional expression of the transgenes in murine Fanca -/- progenitors and human FANCA deficient lymphoblastoid cell lines. Specific Aim 2: Optimize production of a lentiviral vector pseudotyped with a proprietary PFV envelope using GMP complaint methodology. In this Phase I application, the clinical vector construct and optimized production methodology will finalized. In Phase II, Rimedion will generate vector and complete efficacy and toxicity data for inclusion in an IND filing. The work will lead to a Phase I clinical trial using the novel vector to transduce autologous peripheral blood stem cells from Fanconi anemia patients. As discussed in our application, the proof-of-principle has been well established that gene transfer can correct the hematologic defects of this disease, the efficiency of gene transfer using prior vector systems has been the major limitation to developing a commerical product. Rimedion believes the novel vector system described will provide a curative therapy for this genetic disease. PUBLIC HEALTH RELEVANCE: Gene therapy for Fanconi anemia has been successful in murine models but human cures have been limited by the low transduction efficiency of retroviral vectors. Rimedion willutilize a novel lentiviral vector combined with a proprietary foamy virus envelope to improve efficiency and decrease toxicity of gene transfer. Rimedion will optimize the vector and production methods in this application enabling a Phase I clinical trial.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government